https://european-biotechnology.net/wp-content/uploads/2026/01/pexels-abdoo-35143804-1030x687-1.jpg6871030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-01-23 15:23:072026-01-23 15:23:07London-based Ellipses licenses another oncologic asset from Chinese pharma
https://european-biotechnology.net/wp-content/uploads/2026/01/francesco-gallarotti-ruQHpukrN7c-unsplash.jpg427640Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-01-21 18:26:422026-01-21 18:26:42Oxford-based cancer vaccine company Infinitopes closes $35 million seed round
https://european-biotechnology.net/wp-content/uploads/2026/01/JPM-Week-SF-Bay-Bridge-1030x773-1.jpg7731030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-01-21 15:39:022026-01-21 15:39:02A changing playing field: Observations of the 2026 JP Morgan Healthcare Conference from a European perspective
https://european-biotechnology.net/wp-content/uploads/2026/01/V2-960x540_realistic-scene-with-elderly-care-senior-people.jpeg.webp540960Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-01-20 09:27:182026-01-20 09:27:18Heidelberg-based Exciva secures €51M to tackle agitation in Alzheimer’s care
